Acute Heart Failure - Pipeline Review, H2 2016

  • ID: 3804677
  • Report
  • 70 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Amgen Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Trevena, Inc.
  • MORE
Acute Heart Failure - Pipeline Review, H2 2016

Summary

‘Acute Heart Failure - Pipeline Review, H2 2016’, provides an overview of the Acute Heart Failure pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Heart Failure and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Heart Failure
- The report reviews pipeline therapeutics for Acute Heart Failure by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Heart Failure therapeutics and enlists all their major and minor projects
- The report assesses Acute Heart Failure therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Heart Failure

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Heart Failure
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Heart Failure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Amgen Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Trevena, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Acute Heart Failure Overview

Therapeutics Development

Pipeline Products for Acute Heart Failure - Overview

Acute Heart Failure - Therapeutics under Development by Companies

Acute Heart Failure - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Acute Heart Failure - Products under Development by Companies

Acute Heart Failure - Companies Involved in Therapeutics Development

Amgen Inc.

Capricor Therapeutics, Inc.

Eli Lilly and Company

Lee's Pharmaceutical Holdings Limited

Novartis AG

Ono Pharmaceutical Co., Ltd.

PhaseBio Pharmaceuticals, Inc.

Trevena, Inc.

Acute Heart Failure - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

cenderitide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

istaroxime - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omecamtiv mecarbil MR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-4232 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PB-1046 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ruboxistaurin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

serelaxin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRV-120023 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ularitide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Acute Heart Failure - Dormant Projects

Acute Heart Failure - Discontinued Products

Acute Heart Failure - Product Development Milestones

Featured News & Press Releases

Dec 11, 2015: Cardiorentis' Ularitide Receives FDA Fast Track Designation for the Treatment of Acute Decompensated Heart Failure

May 22, 2015: Cardiorentis Completes Enrollment in Pivotal Phase III Clinical Trial of Ularitide for Acute Heart Failure

Oct 16, 2014: Cardiorentis AG and Roche Announce Collaboration to Establish Therapeutic Impact of Ularitide

Oct 09, 2014: Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation

May 23, 2014: Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure

May 16, 2014: FDA issues Complete Response Letter for RLX030 for acute heart failure

Mar 27, 2014: Novartis to work with FDA on path forward for RLX030 for acute heart failure following Advisory Committee outcome

Mar 25, 2014: FDA Staff Says Novartis’ Serelaxin Shouldn’t Be Approved

Jan 24, 2014: Novartis Europharm's Reasanz Receives CHMP Negative Opinion

Jan 24, 2014: Novartis to request re-examination of serelaxin in acute heart failure for conditional marketing authorization in EU

Dec 02, 2013: Paladin Announces Filing of New Drug Submission for RLX030 (Serelaxin)

Sep 03, 2013: Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil

Sep 02, 2013: Novartis' serelaxin improved symptoms and mortality across multiple subgroups of patients with acute heart failure

Jun 21, 2013: Novartis's Serelaxin Receives FDA Breakthrough Therapy Designation For Acute Heart Failure

Mar 18, 2013: Cytokinetics Announces Update To Heart Failure Program

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 70List of Tables

Number of Products under Development for Acute Heart Failure, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Acute Heart Failure - Pipeline by Amgen Inc., H2 2016

Acute Heart Failure - Pipeline by Capricor Therapeutics, Inc., H2 2016

Acute Heart Failure - Pipeline by Eli Lilly and Company, H2 2016

Acute Heart Failure - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016

Acute Heart Failure - Pipeline by Novartis AG, H2 2016

Acute Heart Failure - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016

Acute Heart Failure - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016

Acute Heart Failure - Pipeline by Trevena, Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Acute Heart Failure - Dormant Projects, H2 2016

Acute Heart Failure - Discontinued Products, H2 2016 56List of Figures

Number of Products under Development for Acute Heart Failure, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Amgen Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Trevena, Inc.
  • MORE
Acute Heart Failure Acute heart failure is defined as sudden change in heart functions (inability of heart to pump enough blood to meet body’s demand). Symptoms include shortness of breath, weakness, fatigue, irregular or fast heartbeat and coughing and wheezing. Predisposing factors include high blood pressure, diabetes, coronary artery disease, inherited heart defects, and a damaged or inflamed heart. Treatment includes angiotensin-converting enzyme (ACE) inhibitors, beta blockers, diuretics and surgery.

Acute Heart Failure pipeline therapeutics constitutes close to 9 molecules. which approximately 9 molecules are developed by Companies.The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 2 and 2 respectively.

Our latest report Acute Heart Failure – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Acute Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Acute Heart Failure and features dormant and discontinued projects.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Amgen Inc.
Capricor Therapeutics, Inc.
Eli Lilly and Company
Lee's Pharmaceutical Holdings Limited
Novartis AG
Ono Pharmaceutical Co., Ltd.
PhaseBio Pharmaceuticals, Inc.
Trevena, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll